主页 > 医学文档 >
【文摘发布】[Antimicrob Agents Chemother.] 人源单克隆
题目：Defining limits of humanized neutralizing monoclonal antibody treatment for West Nile virus neurological infection in a hamster model.
作者：Morrey JD, Siddharthan V, Olsen AL, et al.
摘要：A potent neutralizing anti-WNV humanized monoclonal antibody, hE16, when administered intraperitoneally (i.p.), was previously shown to improve the survival of West Nile virus (WNV)-infected hamsters, even after the virus had infected neurons in the brain. In this study, we evaluated the therapeutic limit of hE16 for treatment of West Nile virus infection in hamsters by comparing single-dose peripheral (i.p) therapy with direct administration into the pons through a convection-enhanced delivery (CED) system. Treatment at day 5 after infection with hE16 by peripheral or CED routes were equally effective at reducing morbidity and mortality. In contrast, at day 6 only the treatment by CED protected hamsters from lethal infection. These experiments suggest that hE16 can directly control WNV infection in the central nervous system. In support of this, intraperitoneally administered hE16 was detected in a time-dependent manner in the serum, CSF, cerebral cortex, brain stem and spinal cord in CSF. A linear relationship between hE16 dose and serum concentration was observed, and maximal therapeutic activity occurred at doses of 0.32 mg/kg or higher, which produced serum hE16 concentrations of 1.3 microg/mL or higher. Overall, these data suggest that in hamsters hE16 can ameliorate neurological disease after significant viral replication has occurred, although there is a time-window that limits therapeutic efficacy.
PMID: 17452485 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 来源：Antimicrob Agents Chemother. 2007 Apr 23;
来源：抗微生物制剂和化学治疗 2007年4月23日
题目：Defining limits of humanized neutralizing monoclonal antibody treatment for West Nile virus neurological infection in a hamster model.
题目：确定人源单克隆抗体治疗苍鼠神经系统西尼罗病毒感染的剂量范围
作者：Morrey JD, Siddharthan V, Olsen AL, et al.
摘要：A potent neutralizing anti-WNV humanized monoclonal antibody, hE16, when administered intraperitoneally (i.p.), was previously shown to improve the survival of West Nile virus (WNV)-infected hamsters, even after the virus had infected neurons in the brain.
背景：有中和抗原表位能力的抗西尼罗病毒的人源单克隆抗体－hE16。既往研究表明对西尼罗感染、甚至已累及大脑神经元苍鼠，向腹膜内注射该药可以提高患病苍鼠存活率。
In this study, we evaluated the therapeutic limit of hE16 for treatment of West Nile virus infection in hamsters by comparing single-dose peripheral (i.p) therapy with direct administration into the pons through a convection-enhanced delivery (CED) system 编译：中文字数392
2007年4月23日在《抗微生物制剂和化学治疗》杂志Morrey JD学者发表的一项研究表明在苍鼠西尼罗病毒感染后期，人源单克隆抗体hE16可改善苍鼠神经系统疾病，虽然在“窗口期”未见明显明显疗效。
有中和抗原表位能力的抗西尼罗病毒的人源单克隆抗体－hE16，既往研究表明对西尼罗感染、甚至已累及大脑神经元苍鼠，向腹膜内注射该药可以提高患病苍鼠存活率。在本研究试图通过比较单次外周给药和利用对流增强给药系统(CED)直接注入脑桥评估hE16治疗剂量范围。结果显示：外周和CED途径注射给药法治疗的第5日就减少患病小鼠发病率和死亡率而言，两种方法同样有效。相反，在第6日，仅接受CED途径注射给药的小鼠未见致死性感染。以上结果表明hE16在中枢神经系统可直接控制西尼罗病毒感染。为支持上述结论，在外周注射后不同时间点监测血清、脑脊液、脑皮质、脑干和脊髓hE16浓度。结果显示hE16剂量与血清hE16浓度呈线性相关，注射剂量≥0.32 mg/kg时，血清hE16浓度≥1.3 microg/m显示最佳治疗效能。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-28 05:11
医学,生命科学网